Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.
Thirty patients suffering from essential hypertension were treated successively with placebo, hydralazine alone, and pindolol (Viskén) combined with hydralazine. As compared to placebo hydralazine brought about a statistically significant reduction in blood pressure and an increase in pulse rate; palpitation was an irritating side-effect. Combining hydralazine and pindolol caused an additional fall in blood pressure (2 p less than 0.001) and the pulse rate decreased (2 p less than 0.001). This combination treatment had a favourable effect on the palpitation and angina pectoris also.
D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008875:Middle Aged; D010869:Pindolol / Q000627:therapeutic use*; D010919:Placebos; D011674:Pulse / Q000187:drug effects
D010919:Placebos; D006830:Hydralazine; D010869:Pindolol